No headlines found.
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
PRNewswire (Thu, 10-Sep 9:00 AM ET)
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
PRNewswire (Wed, 22-Jul 8:30 AM ET)
PRNewswire (Mon, 6-Jul 8:45 AM ET)
PRNewswire (Mon, 29-Jun 9:30 AM ET)
EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
PRNewswire (Mon, 22-Jun 9:00 AM ET)
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
PRNewswire (Thu, 11-Jun 9:00 AM ET)
Neurosense Therapeutics Ltd. - Warrant trades on the stock market under the symbol NRSNW.
As of September 10, 2026, NRSNW stock price was flat at $0.05 with 6 million shares trading.
NRSNW has a market cap of $0.00. This is considered a Sub-Micro Cap stock.
In the last 3 years, NRSNW traded as high as $1.06 and as low as $.04.
NRSNW has underperformed the market in the last year with a return of -89.1%, while the SPY ETF gained +17.8%. In the last 3 month period, NRSNW fell short of the market, returning -65.5%, while SPY returned +3.2%. However, in the most recent 2 weeks NRSNW has outperformed the stock market by returning +26.6%, while SPY returned -1.0%.
NRSNW support price is $.03 and resistance is $.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NRSNW shares will trade within this expected range on the day.
